Physician profile
Brandon J Baartman
NPI 1124464664
$225,608.99
in general payments reported to CMS, 2019-2025
34 companies · $135K in 2025
The $135K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $8,244 · 2020: $13K · 2021: $2,641 · 2022: $23K · 2023: $29K · 2024: $14K · 2025: $135K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $162K · Long Term Medical Supply Or Device Loan: $7,475 · Food and Beverage: $4,344 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,625 · Travel and Lodging: $1,493 · Honoraria: $490 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $162,154.95 |
| Long Term Medical Supply Or Device Loan | $7,474.85 |
| Food and Beverage | $4,344.12 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,625.00 |
| Travel and Lodging | $1,493.06 |
| Honoraria | $489.59 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beaver-Visitec International, INC. | $108,035.00 | 2023-2025 | |
| Glaukos Corporation | $39,342.76 | 2019-2025 | Epioxa, Kxl System, Travoprost Intraocular Implant - Idose |
| Sight Sciences, INC. | $38,414.50 | 2019-2025 | Tearcare System, Sion Surgical Instrument, Omni Surgical System |
| Rxsight INC | $22,650.18 | 2020-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Alcon Research LLC | $8,860.20 | 2023-2025 | Ngenuity |
| Alcon Vision LLC | $3,536.80 | 2019-2025 | Clareon, Centurion, Hydrus Microstent |
| New World Medical,INC. | $1,424.77 | 2021-2023 | |
| Abbvie INC. | $580.88 | 2022-2025 | Durysta, Xen Glaucoma Treatment System |
| Kowa Pharmaceuticals America, INC. | $464.00 | 2025 | |
| Samsara Vision | $329.64 | 2023-2024 | |
| Biotissue Holdings INC. | $296.67 | 2022-2024 | |
| Optos, INC. | $185.35 | 2022 | |
| Hoya Surgical Optics, INC | $178.00 | 2023 | |
| Ocular Therapeutix, INC. | $174.99 | 2021-2024 | Dextenza |
| Sun Pharmaceutical Industries INC. | $162.33 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $143.20 | 2019-2021 | |
| Shire North American Group INC | $123.52 | 2019 | |
| Bausch & Lomb Americas INC. | $93.89 | 2023-2024 | Vyzulta, Miebo, Xiidra |
| Tarsus Pharmaceuticals, INC. | $86.99 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $80.19 | 2022-2024 | Tyrvaya, Ryzumvi |
| Mallinckrodt Hospital Products INC. | $70.43 | 2022 | |
| Allergan, INC. | $55.74 | 2021-2022 | |
| Horizon Therapeutics Plc | $52.71 | 2023 | Tepezza |
| Rayner Intraocular Lenses Limited | $49.44 | 2023 | Rayone Spheric, Rayone Aspheric, Rayone Emv |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $48.13 | 2020 | |
| Novartis Pharmaceuticals Corporation | $37.39 | 2022-2023 | |
| Dompe US, INC. | $31.86 | 2021-2024 | Oxervate |
| Harrow Eye, LLC | $22.30 | 2023 | Iheezo |
| Amgen INC. | $18.47 | 2025 | Tepezza |
| Carl Zeiss Meditec USA, INC. | $16.37 | 2024 | |
| Johnson & Johnson Surgical Vision, INC. | $15.39 | 2023 | Tecnis Simplicity |
| Omeros Corporation | $14.97 | 2020 | |
| Quidel Corporation | $11.93 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$202,298.90 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Baartman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.